These studies indicate that the long isoform of IRAK4 plays a critical role in the activation of chronic innate immune signaling in MDS and AML and thus is a candidate therapeutic target (Smith et al., 2019). This evidence concerns the gene IRAK4 and acute myeloid leukemia.